- Home
- THFF vs CRVS Comparison
THFF vs CRVS Comparison
Compare THFF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- CRVS
- Stock Information
- Founded
- THFF 1984
- CRVS 2014
- Country
- THFF United States
- CRVS United States
- Employees
- THFF N/A
- CRVS N/A
- Industry
- THFF Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- THFF Finance
- CRVS Health Care
- Exchange
- THFF Nasdaq
- CRVS Nasdaq
- Market Cap
- THFF 599.3M
- CRVS 516.0M
- IPO Year
- THFF N/A
- CRVS 2016
- Fundamental
- Price
- THFF $47.54
- CRVS $5.22
- Analyst Decision
- THFF Hold
- CRVS Strong Buy
- Analyst Count
- THFF 1
- CRVS 5
- Target Price
- THFF $45.00
- CRVS $12.38
- AVG Volume (30 Days)
- THFF 42.5K
- CRVS 1.6M
- Earning Date
- THFF 01-28-2025
- CRVS 11-12-2024
- Dividend Yield
- THFF 4.29%
- CRVS N/A
- EPS Growth
- THFF N/A
- CRVS N/A
- EPS
- THFF 3.68
- CRVS N/A
- Revenue
- THFF $190,119,000.00
- CRVS N/A
- Revenue This Year
- THFF N/A
- CRVS N/A
- Revenue Next Year
- THFF $11.39
- CRVS N/A
- P/E Ratio
- THFF $12.93
- CRVS N/A
- Revenue Growth
- THFF N/A
- CRVS N/A
- 52 Week Low
- THFF $34.58
- CRVS $1.30
- 52 Week High
- THFF $51.87
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- THFF 56.67
- CRVS 41.23
- Support Level
- THFF $42.65
- CRVS $4.60
- Resistance Level
- THFF $46.74
- CRVS $6.47
- Average True Range (ATR)
- THFF 1.11
- CRVS 0.39
- MACD
- THFF 0.26
- CRVS 0.06
- Stochastic Oscillator
- THFF 94.77
- CRVS 33.16
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services, and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).